PTPI Company Profile and Key Details

Petros Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2025, missed forecasts by 251.52%. The prior quarter beat by 82.76%. Over the last six quarters, Apple has recorded several small beats. These include -112.05% in March 27, 2024.

The stock is currently mid-range between its 52-week high and low $0.00 and $0.03. With a market capitalization of about $245.76 thousand, Petros Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 113.94 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Petros Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Fady Boctor, the company employs approximately 3 people and listed since December 02, 2020. Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions.

PTPI has shown mixed momentum, gaining 23.67% over the past week and -97.58% over the past quarter, though year-to-date performance is down -99.64%. Short-term trend indicators are bullishly aligned (SMA20 7.14%, SMA50 -88.57%, SMA200 -99.33%). The stock’s 14-day RSI is 29.49 (weak momentum), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.79% below its high and over 47.79% above its low. Average 10-day trading volume of 101.21 thousand shares is slightly above the 3-month average of 91.93 thousand, indicating heightened recent market interest.

Petros Pharmaceuticals, Inc. has 42.37 million shares outstanding. The public float is 28.93 million shares, elevated short interest at 25.07% of float. This equals 493.83 thousand shares. The short ratio is 0.17 days. Institutional investors hold 13.48% of the float. Insiders own 24.08%.

Petros Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Petros Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 72.41%, with price expected at $0.01 by September 23, 2026, within a range of $0.01 to $0.01 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 08, 2026, with a range of $0.00 to $0.05. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 10, 2027, within a range of $0.00 to $0.60.

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) shares are down -99.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Petros Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 0.0. Our AI forecast model points to short-term strength (72.41% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Petros Pharmaceuticals, Inc. trades at a P/E ratio of 0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.45 suggesting the stock is closer to book value. The P/FCF stands at -0.08, also above market averages.